The P-III trial evaluating Imfinzi + Pt-based CT, followed by Imfinzi with Lynparza or Imfinzi alone as maintenance therapy vs Pt-based CT alone in 699 patients at 253 study locations across 22 countries incl. the US, EU, South America & Asia
The results showed a significant & clinical improvement in PFS, greater benefits were seen with the combination of Lynparza + Imfinzi as maintenance treatment while OS data were immature & favorable trends were reported for both a treatment regimen
The safety & tolerability profile was consistent with prior clinical trials & the known profile of the individual’s therapies. The company will discuss the results with the regulatory authorities
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso (osimertinib) for the Treatment of EGFR-Mutated Advanced Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
